FDA partners with Alzheimer’s advocacy groups

The FDA is collaborating with a number of Alzheimer’s groups including the Alzheimer’s Association within the community to support the development of new biomarkers and improved diagnosis.

Margaret A. Hamburg, MD, present FDA commissioner, has announced alliances with a number of advocacy groups, according to an online statement made last week.

“We at FDA join in recognizing those who have made these important contributions and commitments,” remarked Hamburg. “We also recognize and applaud the contributions of each and every member of the Alzheimer’s Association who have come to Washington this week to learn more, but also to educate policymakers through their experience, advocacy, and personal stories. Like all of them, we at FDA are committed to doing our part to meet the immense scientific and social challenges of this disease.”

The FDA is now aligned with the Accelerating Medicines Partnership (AMP) of the National Institutes of Health as well as the Coalition Against Major Disease (CAMD), which aims to support clinical trials that bring forward viable means of detecting onset of Alzheimer’s disease. The FDA has presented a protocol called Drug Development Tool Qualification to help standardize and simulate ideal trial conditions.